An FDA official said there is currently no evidence a longer course of Pfizer’s COVID-19 antiviral treatment would benefit patients experiencing a rebound in symptoms.
Read the full post on Becker's Hospital Review - Healthcare News
FDA: ‘No evidence’ 2nd Paxlovid course stops recurring symptoms
